These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1484 related items for PubMed ID: 12813929

  • 1. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA.
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA.
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [Abstract] [Full Text] [Related]

  • 4. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA.
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [Abstract] [Full Text] [Related]

  • 5. Clinical gene transfer studies for hemophilia B.
    High KA.
    Semin Thromb Hemost; 2004 Apr; 30(2):257-67. PubMed ID: 15118937
    [Abstract] [Full Text] [Related]

  • 6. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C.
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [Abstract] [Full Text] [Related]

  • 7. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD.
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [Abstract] [Full Text] [Related]

  • 8. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.
    Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA.
    Nat Med; 2006 Mar; 12(3):342-7. PubMed ID: 16474400
    [Abstract] [Full Text] [Related]

  • 9. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, Herzog RW, High KA.
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [Abstract] [Full Text] [Related]

  • 10. Gene therapy for hemophilia "A" and "B": efficacy, safety and immune consequences.
    Chuah M, Vandendriessche T.
    Verh K Acad Geneeskd Belg; 2007 Sep; 69(5-6):315-34. PubMed ID: 18351211
    [Abstract] [Full Text] [Related]

  • 11. Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors.
    Couto LB.
    Semin Thromb Hemost; 2004 Apr; 30(2):161-71. PubMed ID: 15118928
    [Abstract] [Full Text] [Related]

  • 12. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ, Kaplitt MG, Stern MB, Eidelberg D.
    Hum Gene Ther; 2001 Aug 10; 12(12):1589-91. PubMed ID: 11529246
    [Abstract] [Full Text] [Related]

  • 13. Gene therapy for haemophilia "A" and "B": efficacy, safety and immune consequences.
    Chuah MK, Vandendriessche T.
    Bull Mem Acad R Med Belg; 2007 Aug 10; 162(5-6):357-61. PubMed ID: 18405006
    [Abstract] [Full Text] [Related]

  • 14. No evidence for germ-line transmission following prenatal and early postnatal AAV-mediated gene delivery.
    Jakob M, Mühle C, Park J, Weiss S, Waddington S, Schneider H.
    J Gene Med; 2005 May 10; 7(5):630-7. PubMed ID: 15693035
    [Abstract] [Full Text] [Related]

  • 15. AAV-mediated gene transfer for hemophilia.
    High KA.
    Ann N Y Acad Sci; 2001 Dec 10; 953():64-74. PubMed ID: 11795424
    [Abstract] [Full Text] [Related]

  • 16. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
    Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW.
    Gene Ther; 2005 Oct 10; 12(19):1453-64. PubMed ID: 15889137
    [Abstract] [Full Text] [Related]

  • 17. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
    Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE.
    Gene Ther; 1998 Jan 10; 5(1):40-9. PubMed ID: 9536263
    [Abstract] [Full Text] [Related]

  • 18. Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
    Fabb SA, Dickson JG.
    Curr Opin Mol Ther; 2000 Oct 10; 2(5):601-6. PubMed ID: 11249763
    [Abstract] [Full Text] [Related]

  • 19. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
    Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF, Stafford DW, Patel S, Thompson AR, Nichols T, Read MS, Bellinger DA, Brinkhous KM, Kay MA.
    Nat Med; 1999 Jan 10; 5(1):64-70. PubMed ID: 9883841
    [Abstract] [Full Text] [Related]

  • 20. Gene therapy for hemophilia.
    Ponder KP.
    Curr Opin Hematol; 2006 Sep 10; 13(5):301-7. PubMed ID: 16888433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 75.